SCYNEXIS

SCYNEXIS, Inc. is a biotechnology firm based in the U.S. dedicated to developing therapies for fungal infections. The company's flagship product, BREXAFEMME (ibrexafungerp tablets), has received approval for the treatment of vulvovaginal candidiasis (VVC). Furthermore, SCYNEXIS is progressing ibrexafungerp, its leading drug candidate, as both an oral and intravenous medicine designed to address various fungal conditions, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and challenging refractory invasive fungal infections. Ibrexafungerp has successfully completed the Phase 3 CANDLE study, which evaluated its effectiveness in preventing recurrent VVC. SCYNEXIS has also established collaborative research and commercialization agreements for ibrexafungerp with partners such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. Founded in 1999, the company is headquartered in Jersey City, New Jersey, and changed its name from SCYNEXIS Chemistry & Automation, Inc. to its current designation in June 2002.